Exscientia PLC (EXAI) Noticias

Ok thanks

Calls were before the announcement.

Hello, why buy the 5 calls ?? Didn't the buyout happen already,and what was the buyout price offer ??

Or are you expecting a bidding war since 3 bigger players have 500million plus invested into EXAI...I thought Sanfi & Bristol Squibb & another big company have a stake in them...
Thanks interesting Exai

Got $5.00 calls 01/17/25.

$EXAI - Still seems to be under the radar even after the Recursion news. I have been accumulating for the most part under $5.

https://www.benzinga.com/general/biotech/24/08/40271278/ai-powered-drug-discovery-firm-exscientia-to-merge-with-nvidia-partner-recursion-pharmaceuticals

EXAI under $6

EXAI under $5

EXAI under $10

It will come, this gives us early ones time to accumulate a little more.

Big institutions need to pile in...Once they do you'll see articles they paid for on Motley fool etc...

still no signof a breakout.

Nope still overbought

Looks like this is our first major turn around.
We we're going to add to. our position last week but
dumped the funds elsewhere.
We'll add if we get a little pull back today.

In a way thats good. I just keep adding to my position. Picked up over a thousand shares this week.
The company's financing through 2024 is qute impressive like three hundred million.
The potential is off the chart.
And a good day to all investors here.
And Thanks
Carl

Down she goes

The monthly stochastic is overbought

Doesn’t look that hideous to me.

Ugly monthly chart

HUGE NEWS = Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges

Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales

Up to $113 million of potential milestone payments in the discovery phase, with $20 million upfront at initiation for three projects

OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilise Exscientia’s AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA, Darmstadt, Germany’s disease expertise in oncology and neuroinflammation, clinical development capabilities and global footprint.

Three potential first-in-class or best-in-class targets have been identified as the initial focus of the partnership. The collaboration allows Merck KGaA, Darmstadt, Germany and Exscientia to identify additional targets in oncology and immunology or other mutually agreed disease areas. Should Exscientia identify additional targets for the collaboration, the company would be responsible for target validation in addition to drug design and eligible for additional discovery milestones.

“We’re pleased that Merck KGaA, Darmstadt, Germany chose our team of experts for this AI-led drug discovery collaboration,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. We look forward to complementing their outstanding scientific acumen with our integrated technology platform and ability to generate novel data in order to address some of the hardest drug design challenges in cancer and immunology."

Under the terms of the agreement, Exscientia will receive an upfront cash payment of $20 million from Merck KGaA, Darmstadt, Germany and will be eligible for discovery, development, regulatory and sales-based milestone payments of up to $674 million in aggregate, if all milestones for all three initial programmes are achieved. If Merck KGaA, Darmstadt, Germany commercialises a therapeutic from one of the initial targets of the collaboration, Exscientia will receive tiered royalties on product sales ranging from mid-single-digits to low-double-digits. The upfront cash payment of $20 million is expected to be reflected in second half 2023 results for Exscientia as cash inflows from collaborations and recognised as revenue over the duration of the agreement.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-looking statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the initiation and duration of Exscientia’s collaboration with Merck and

Using AI to find the next blockbuster drug
This week, AI chipmaker Nvidia placed their bet — investing $50M into AI drug discovery platform Recursion Pharmaceuticals (NASDAQ:RXRX) — sending its stock up 78%.
Drugmakers are already benefiting from using AI to discover new drugs. And in the process, AI is speeding up and reducing the cost of the long and expensive drug development process.
Between 2015 and 2022, the cumulative investment in AI drug development has risen from under $1B to $24.6B.
In the next decade, Morgan Stanley expects AI will help develop an additional 50 drugs with an extra $50B in sales.
Following Nvidia’s investment, other AI drug discovery platforms rose on the news, including Exscientia (NASDAQ:EXAI), AbCellera Biologics (NASDAQ:ABCL) and Relay Therapeutics (NASDAQ:RLAY).
Recursion has five drugs, and Exscientia has three drugs discovered with AI, which are already in human trials. And within the startup sector, AI drug discovery has quickly become one of the hottest markets for investment.